COVID-19 and Hypertension: A Mini-Review of Their Mutual Effect
Asian Journal of Research in Infectious Diseases,
Cases of Coronavirus disease are rapidly increasing across the world. Hypertension is the commonest co-morbidity among COVID-19 infected patients and hypertension is one of the determinants of severity of COVID-19.COVID -19 virus uses ACE-2 as an entry receptor and ACE-2 plays a vital role in blood pressure control in an individual. Certain antihypertensive medications may affect ACE-2 level and hence COVID-19 pathogenesis. At present, while the worlds focus is on the COVID-19, there is a danger that management of other illnesses like hypertension might be overlooked. It is highly recommended to take antihypertensive medications as directed and following healthy lifestyle practices like regular exercise, consuming low salt heart-healthy diet, maintaining a healthy weight and reducing stress, and practicing mindfulness even during this pandemic.
- health control
How to Cite
Mortality Risk of COVID-19 - Statistics and Research - Our World in Data [Internet]. [cited 2021 May 14]. Available: https://ourworldindata.org/mortality-risk-covid
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin M, Bhatia S, Boonyasiri A, Cori A, Cucunubá Z, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis [Internet]. 2020;20(6):669–77. [cited 2021 May 14].
ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19) - American College of Cardiology [Internet]. [cited 2021 May 14].
Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19 [Internet]. Vol. 33, American Journal of Hypertension. Oxford University Press. 2020;373–4. [cited 2021 May 14].
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet]. 2020;395(10229):1054–62. [cited 2021 May 14].
Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc [Internet]. 2020;9(7):e016219. [cited 2021 May 16].
Available from: https://www.ahajournals.org/doi/10.1161/JAHA.120.016219
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med [Internet]. 2020;180(7):934–43. [cited 2021 May 14].
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? [Internet]. The Lancet Respiratory Medicine. Lancet Publishing Group. 2020;8:e21.
[cited 2021 May 15].
Askin L, Tanrıverdi O, Askin HS. The effect of coronavirus disease 2019 on cardiovascular diseases [Internet]. Vol. 114, Arquivos Brasileiros de Cardiologia. Arquivos Brasileiros de Cardiologia. 2020;817–22. [cited 2021 May 22].
Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system [Internet]. Vol. 17, Nature Reviews Cardiology. Nature Research. 2020;259–60. [cited 2021 May 22].
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA - J Am Med Assoc [Internet]. 2020;323(20):2052–9. [cited 2021 Jun 7].
Available from: https://jamanetwork.com/
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension [Internet]. 2020;75(6):1334–57.
[cited 2021 May 14].
Available from: http://ahajournals.org
COVID-19 and Hypertension: What We Know and Dont Know - American College of Cardiology [Internet].
[cited 2021 Jun 7].
Available from: https://www.acc.org/latest-in-cardiology/articles/2020/07/06/08/15/covid-19-and-hypertension
Foëx P, Sear JW. Hypertension: Pathophysiology and treatment. Contin Educ Anaesthesia, Crit Care Pain [Internet]. 2004 Jun 1 [cited 2021 May 14];4(3):71–5.
Available : https://academic.oup.com/bjaed/article/4/3/71/292146
Jia H. Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease [Internet]. Vol. 46, Shock. Lippincott Williams and Wilkins; 2016 [cited 2021 May 14]. 239–48.
Pieruzzi F, Abassi ZA, Keiser HR. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation [Internet]. 1995 Nov 15 [cited 2021 May 14];92(10):3105–12.
Available from: https://www.ahajournals.org/doi/abs/10.1161/01.cir.92.10.3105
Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review [Internet]. Vol. 215, Clinical Immunology. Academic Press Inc.; 2020 [cited 2021 May 14]. p. 108427.
Paz Ocaranza M, Riquelme JA, García L, Jalil JE, Chiong M, Santos RAS, Lavandero S. Counter-regulatory renin–angiotensin system in cardiovascular disease [Internet]. Vol. 17, Nature Reviews Cardiology. Nature Research; 2020 [cited 2021 May 14]. p. 116–29.
Available from: www.nature.com/nrcardio
Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, Farzan M, Wohlford-Lenane C, Perlman S, McCray PB. ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. J Virol [Internet]. 2005 Dec 15 [cited 2021 May 14];79(23):14614–21.
Available from: https://pubmed.ncbi.nlm.nih.gov/16282461/
ACE-2 is shown to be the entry receptor for SARS-CoV-2: R&D Systems [Internet]. [cited 2021 May 14].
Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. JRAAS - J Renin-Angiotensin-Aldosterone Syst [Internet]. 2020 Apr 1 [cited 2021 May 15];21(2).
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med [Internet]. 2005 Aug 10 [cited 2021 May 18];11(8):875–9.
Bosso M, Thanaraj TA, Abu-Farha M, Alanbaei M, Abubaker J, Al-Mulla F. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Vol. 18, Molecular Therapy - Methods and Clinical Development. Cell Press; 2020. p. 321–7.
Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol [Internet]. 2004 Jun [cited 2021 May 22];203(2):631–7.
Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res [Internet]. 2000 Sep 1 [cited 2021 May 22];87(5).
Available from: http://www.circresaha.org.
What is the ACE2 receptor, how is it connected to coronavirus and why might it be key to treating COVID-19? The experts explain [Internet]. [cited 2021 May 16].
Hypertension, health inequities, and implications for COVID-19 - Harvard Health [Internet]. [cited 2021 May 15].
Sheppard JP, Nicholson BD, Lee J, McGagh D, Sherlock J, Koshiaris C, Oke J, Jones NR, Hinton W, Armitage L, Van Hecke O, Lay-Flurrie S, Bankhead CR, Liyanage H, Williams J, Ferreira F, Feher MD, Ashworth AJ, Joy MP, De Lusignan S, Hobbs FDR. Association between Blood Pressure Control and Coronavirus Disease 2019 Outcomes in 45 418 Symptomatic Patients with Hypertension: An Observational Cohort Study. Hypertension [Internet]. 2021 [cited 2021 May 18];77:846–55.
Melo De Oliveira G, Inês M, Rossi D. Review Article Nephrology and Renal Diseases Nephrol Renal Dis. :2020.
Nadar SK, Tayebjee MH, Stowasser M, Byrd JB. Managing hypertension during the COVID-19 pandemic [Internet]. Vol. 34, Journal of Human Hypertension. Springer Nature; 2020 [cited 2021 May 16]. p. 415–7.
Available from: /pmc/articles/PMC7224587/
Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA, Rowan K, Aveyard P, Pavord ID, Watkinson PJ. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: Cohort study including 8.3 million people. Heart [Internet]. 2020 Oct 1 [cited 2021 May 18];106(19):1503–11.
Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, Zhang X, Li Q, Li W, Yang S, Zhao X, Zhao Y, Wang H, Liu Y, Yin Z, Zhang R, Wang R, Yang M, Hui C, Wijns W, Mcevoy JW, Soliman O, Onuma Y, Serruys PW, Tao L, Li F. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J [Internet]. 2020 Jun 7 [cited 2021 May 18];41(22):2058–66.
Available from: /pmc/articles/PMC7314067/
de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, Laredo L, Laosa O, Centeno-Soto GA, Ángeles Gálvez M, Puerro M, González-Rojano E, Pedraza L, de Pablo I, Abad-Santos F, Rodríguez-Mañas L, Gil M, Tobías A, Rodríguez-Miguel A, Rodríguez-Puyol D, Barreira-Hernandez D, Zubiaur P, Santos-Molina E, Pintos-Sánchez E, Navares-Gómez M, Aparicio RM, García-Rosado V, Gutiérrez-Ortega C, Pérez C, Ascaso A, Elvira C. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet [Internet]. 2020 May 30 [cited 2021 Jun 7];395(10238):1705–14.
Available from: www.bifap.org
Ssentongo AE, Ssentongo P, Heilbrunn ES, Lekoubou A, Du P, Liao D, Oh JS, Chinchilli VM. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: Systematic review and meta-analysis. Open Hear [Internet]. 2020 Nov 5 [cited 2021 Jun 7];7(2):1353.
Available from: http://dx.doi.org/10.1136/
Chan CK, Huang YS, Liao HW, Tsai IJ, Sun CY, Pan HC, Chueh JS, Wang JT, Wu VC, Chu TS. Renin-angiotensin-aldosterone system inhibitors and risks of severe acute respiratory syndrome coronavirus 2 infection: A systematic review and meta-analysis. Hypertension [Internet]. 2020 [cited 2021 Jun 7];1563–71.
Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, Wen F, Huang X, Ning G, Wang W. Cell Discovery Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. [cited 2021 May 15];
Available from: http://creativecommons.org/licenses/by/4.0/.Correspondence:YananCao
Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res [Internet]. 2011 [cited 2021 May 16];34:154–60.
Available from: www.nature.com/hr
Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman M V., Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res [Internet]. 2020 Jul 1 [cited 2021 May 18];191:145–7.
Available from: /pmc/articles/PMC7146714/
Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med [Internet]. 2020 May 11
[cited 2021 Jun 7];9(5):1417.
Nadar S, Lip GYH, Pini R. Hypertension and the prothrombotic state  (multiple letters). Vol. 41, Journal of the American College of Cardiology. Elsevier Inc.; 2003;1847.
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med [Internet]. 2020 Apr 23 [cited 2021 May 16];382(17):1653–9.
Danser AHJ. Scientific Newsletter Update on Hypertension Management COVID-19 AND RAS BLOCKERS: A PHARMACOLOGY PERSPECTIVE [Internet]. [cited 2021 May 16].
HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 - American College of Cardiology [Internet].
[Cited 2021 May 16].
Available: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid- 19
Kario K, Morisawa Y, Sukonthasarn A, Turana Y, Chia YC, Park S, Wang TD, Chen CH, Tay JC, Li Y, Wang JG. COVID-19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network [Internet]. Vol. 22, Journal of Clinical Hypertension. Blackwell Publishing Inc.; 2020 [cited 2021 Jun 7]. p. 1109–19.
Abstract View: 194 times
PDF Download: 57 times